Treatment of carotid atherosclerotic plaque Dengzhan Shengmai capsule versus Aspirin

Author(s): Jeske Dehne

Background For the treatment of carotid atherosclerosis, aspirin is a highly efficient antiplatelet drug [1]. However, the drug's significant risk of bleeding incidents necessitates the search for a safer substitute with as much or more efficacy as aspirin [2]. Dengzhan Shengmai pills have been used extensively to treat carotid atherosclerosis, and if they are found to be non-inferior to aspirin, they may be preferred over that drug due to its many benefits [3]. In order to determine if DZSM is noninferior to aspirin for the treatment of carotid atherosclerotic plaques, we performed a randomised experiment [4]. Methods We conducted a prospective, open-label, randomised non-inferiority study in a single centre [5]. Randomly allocated patients with carotid atherosclerotic plaques were recruited and given either DZSM capsules or the main result was the Aspirin's mean effect on carotid intima medium thickness [6]. The time following Ischemic events, lumen stenosis rate, lipid levels, and plaque scores, length, numbers, and vulnerability were considered secondary outcomes [7]. The findings of laboratory tests and adverse occurrences were noted as safety outcomes [8]. When the lower limit of the one-sided confidence of the difference in IMT between groups was more than -0.06 mm, the non-inferiority of DZSM was shown margin of noninferiority. Patients were enrolled in this experiment, which has been filed at ClinicalTrials [9]. gov, and there was no statistically significant demographic difference between the groups [10].